Two peptides consisting of amino acids 1-30 and 31-67 of the N-terminus of the prohormone of atrial natriuretic factor (pro-ANF) that have vasodilatory and natriuretic properties were investigated to determine if they circulate in humans. Specific and sensitive radioimmunoassays were developed to amino acids 1-30, 31-67, and 99-126 of pro-ANF. Evaluation of human plasma that had been subjected to reverse-phase high-pressure liquid chromatography suggested that pro-ANFs 1-30 and 31-67 as well as ANF were distinct peaks in human plasma corresponding exactly to pure synthetic peaks of these peptides on high-pressure liquid chromatography. Molecular weight determination of the endogenous immunoreactive peptides measured in plasma by G-50 Sephadex gel permeation chromatography revealed that the pro-ANF 1-30 radioimmunoassay recognized a peptide of 10,000 MW, which is consistent with it measuring the whole N-terminus of pro-ANF (amino acids 1-98) but without ANF (C-terminus) attached to it. The pro-ANF 31-67 radioimmunoassay recognized mainly (more than 95%) a peptide of 3,900-4,000 MW, which corresponds closely with its actual molecular weight of 3,878. Our ANF radioimmunoassay recognizes a peptide in plasma of 3,000 MW with the known molecular weight of ANF being 3,081. The mean circulating concentrations of immunoreactive pro-ANF 1-98, pro-ANF 31-67, and ANF in 54 control subjects were 531±25, 371±+18, and 22±1 fmol/ml (±SEM), respectively. Thirty patients with varying severity of congestive heart failure were also studied. The N-terminus, C-terminus, and pro-ANF 31-67 increased: twofold for New York Heart Association functional Class II, threefold to ninefold for Class III, and 10to 20-fold for Class IV patients with congestive heart failure. Thus, the N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of pro-ANF as well as ANF circulate normally and increase proportionately to the increasing severity of congestive heart failure. However, because the pro-ANF 31-67 radioimmunoassay was the only assay that discriminated between patients with Class I congestive heart failure and control subjects, this assay may be the most useful to accurately classify the severity of congestive heart failure. A trial natriuretic factor (ANF), the 28amino-acid carboxy-terminal end of the 126amino-acid prohormone, has natriuretic, diuretic, and potent vasodilator properties.1-4 Recently, we have found that peptides from the N-terminal end of this prohormone consisting of amino acids 1-30 (pro-ANF 1-30) and 31-67 (pro-ANF 31-67) have vasodilatory properties5 and that pro-ANF 31-67 has potent natriuretic and diuretic properties nearly equal to that of ANF.6 These peptides' vasodilatory effects were associated with
a fourfold to fivefold increase in cyclic GMP (cGMP), which was found to be due to activation of particulate guanylate cyclase (E.C. 4.6.1.2).5 Pro-ANF 1-30 and pro-ANF 31-67 also have been found to enhance the guanylate cyclase-cGMP system in the kidney, similar to ANF. 7 The present study details new radioimmunoassays devised to determine if these peptides (pro-ANF 1-30 and pro-ANF 31-67) circulate normally in humans. When the N-terminus (amino acids 1-98) and a 4,000 -MW peptide from the midportion of N-terminus of pro-ANF consistent with pro-ANF 31-67 were found to circulate in 54 normal subjects, this study was extended to determine if the levels of these peptides change in patients with salt and water metabolism abnormalities. Thirty patients with congestive heart failure who were subdivided on the basis of the severity of their symptoms by New York Heart Association (NYHA) functional Classification were studied.
Methods

Control Subjects
Fifty-four control subjects (35 men and 19 women; age 22-49 years; all normotensive with blood pressures less than 138/88 mm Hg) were studied. These subjects had heart rates ranging from 60 to 92 beats/min with respiration rates between 12 and 14/min. Blood pressure, heart rate, weight, height, age, and gender of each are shown in Table 1 . None of these volunteers had any known disease. Of importance, none of these subjects had any salt or water metabolism abnormality. None of the 54 subjects were on any medications except seven of the 19 women, who were on birth control pills. (The results are subdivided below for women on birth control pills.)
Patients
Thirty patients with congestive heart failure were also evaluated to determine if the circulating concentrations of these peptides vary with abnormal salt and water metabolism. These patients were subdivided into four groups (I-IV) according to the NYHA's functional Classification of symptomology associated with congestive heart failure.8 These 30 patients had respiration rates of 12-18/min with heart rates of 72-96 beats/min. Their blood pressure ranged from 110/68 to 160/94 mm Hg ( Table 2) . The first two patients tested under the NYHA Class IV classification in Table 2 had pulmonary edema clinically, which was confirmed by chest roentgenograms. None of these patients with congestive heart failure had any discernible renal impairment; the serum creatinine of all patients was less than 1.5 mg/dl. Informed consent was obtained from both the control subjects and the patients with congestive heart failure after the nature and possible consequences of the studies were fully explained. This study was approved by the Human Use Com-mittee of both the University of Arkansas for Medical Sciences and the John L. McClellan Memorial Veterans Hospital. Antisera to Pro-ANF 1-30 and 31-67
Radioimmunoassays to determine which portion of human pro-ANF circulates in human plasma were devised to amino acids 1-30, 31-67, and 99-126 with synthetic 1251-labeled peptides labeled by the Idogen method9 and antisera purchased from Peninsula Laboratories (Belmont, California). These antibodies were produced by conjugating each respective peptide to thyroglobulin with subsequent subcutaneous injection into rabbits. 10 Purity of Pro-ANF Peptides 1-30, 31-67, and To test these peptides for purity, we subjected them to reverse-phase high-pressure liquid chromatography using a Novapak C-18 (5 g) cartridge column. The Waters Associates liquid chromatograph was comprised of a Model 680 gradient controller, two Model 510 high-pressure liquid chromatography pumps, a Model U6K injector, and a Model 481 LC spectrophotometer. The flow rate was 1 ml/min with 0.1% trifluroacetate solvent in pump A and 60% acetonitrile in 0.1% trifluroacetate in pump B. Separation was achieved using a linear gradient of 0-60% solvent B over 40 minutes. The ultraviolet deflection was set at 210 nm, and 1 gg/ml of each peptide was injected. Each peptide was first run separately to determine its retention time. After their respective retention times were determined, 10 ,ul of each peptide (1 ,ug/,l) were combined, and 25 gl of this pool was evaluated at the above flow rate by being placed into pump A. Three separate, distinct peaks were found at 32%, 48.5%, and 39% acetonitrile for ANF, pro-ANF 1-30, and pro-ANF 31-67, respectively, as shown in "Results." Extraction of Pro-ANF 1-30 and 31-67
From Plasma
To determine if these peptides circulate in humans, samples from control subjects and patients with congestive heart failure were collected in cold tubes of 5 ml EDTA, transported on ice, and immediately centrifuged at 3,000g for 15 minutes. After centrifugation, the plasma was extracted with 100% ethanol (1:1 dilution), vortexed, and allowed to stand at 40 C for 30 minutes, which is similar to the method previously described to extract somatostatin for assay.1' When handled in this manner, we have found in a series of experiments comparing samples in EDTA alone with samples from the same patients collected in EDTA plus the protease inhibitors aprotinin and/or leupeptins that the addition of a protease inhibitor is not necessary. Identical results for all three peptides were found with or without the protease(s) inhibitors present. After 30 minutes at 40 C, the samples were centrifuged at 3,000g for 15 minutes and the supernatants taken to dryness via 313  2  446  262   3  592  345  4  410  265  5  844  660  6  860  608  7  849  497  8  487  460  9  818  506  10  843  453  11  781  197  12  989  637  13  947  764  14  513  313  15  303  177  16  473  455  17  576  144  18  506  319  19  505  326  20  326  223  21  346  212  22  382  373  23  331  209  24  501  362  25  351  249  26  444  289  27  483  286  28  557  495  29  385  454  30  572  521  31  523  481  32  382  260  33  684  327  34  565  352  35  999  474  36  437  528  37  580  481  38  701  563  39  448  398  40  509  429  41  357  284  42  347  335  43  356  316  44  423  284  45  485  485  46  448  377  47  423  253  48  343  259  49  451  305  50  493  212  51  585  277  52  470  435  53  437  261  54  344  277  Mean  531  371  SEM  25  18 Pro-ANF, prohormone atrial natriuretic factor. 18 18 17  22  22  24  28  23  20  20  16  28  20  24   21  30  23  26  19  19  22  24  19  20  20  22  28  23  20  28  23  22  17  14  21  22  25  26  18  16  20  19  20  21  25  27  20  25  24  24  19  23  18  23 Pro-ANF, prohormone atrial natriuretic factor; NYHA, New York Heart Association. The mean circulating concentration of pro-ANFs 1-98, 31-67, and ANF were significantly higher for the Class IV patients versus Class 1-111 and control subjects, whereas Class III patients' circulating concentrations of these peptides were significantly higher than those for Class II or I or control subjects at p<0.001 by Student's t test for unpaired values. Pro-ANFs 1-98, 31-67, and ANF were significantly higher (p<0.05) for Class II versus Class I and control subjects by Student's t test for unpaired values. controlled nitrogen flow. For the radioimmunoassay of all three peptides, the plasma sample of persons without any known disease (control subjects) was 200 gl, which was chosen because this plasma volume closely approximates the IC50 of the respective radioimmunoassays (see Figures 1-3 ). For the patients with congestive heart failure, 100 gcl dried ethanol-extracted plasma of each patient 100 PEPTIDE (f mol/tube) was first assayed to determine if it approximated the IC50 of the respective radioimmunoassay curves. For the patients with Class I congestive heart failure, 100 ,l was the concentration of plasma that best fit their respective radioimmunoassay curves. For the patients with more severe congestive heart failure, this 100-,l dried plasma sample had to be diluted with varying amounts of 0.1 M phosphate buffer (pH 7.4) to fit the radioimmunoassay curves as shown in Figures 1-3 . Thus, for patients with the most severe (Class IV) congestive heart failure, 100 jAl of dried plasma was redissolved in 1 ml phosphate buffer. One hundred microliters of this (1:10) dilution was then assayed to correspond closely to the radioimmunoassay curves. This 1:10 dilution of the plasma sample is referred to as a 10-,ul plasma sample in Figures 1-3 . Likewise, the 20-Ad plasma samples in Figures 1-3 were obtained by redissolving the 100 g1d dried extracted plasma with 500 ,£1 0.1 M phosphate buffer to make a 1:5 dilution (i.e., 20% of the original plasma concentration). For all of the dilutions in Figures 1-3 , the final volume assayed, regardless of the amount diluted, was 100 ,ul. The drying process with nitrogen takes approximately 2 hours for 100-gl samples and 4 hours for 200-/ul samples; the samples are then ready for radioimmunoassay. We have found that at this point these samples can be frozen at -70°C with no loss in the concentration of the various peptides measured.
Radioimmunoassays of Pro-ANF 1-30 and Pro-ANF 31-67
For each radioimmunoassay, the extracted plasma was first reconstituted in 100 Al 0.1 M phosphate buffer (pH 7.4) containing 0.05 M NaCl, 0.1% bovine serum albumin, 0.1% Triton X-100, and 1000 FIGURE 1. Representative standard curve for the prohormone ofatrial natriuretic factor (pro-ANF) 1-30 radioimmunoassay with dilution curves of ANF, pro-ANF 31-67, and plasma extracts of control subjects and patients with congestive heart failure. There was less than 0.5% cross-reactivity with either ANF or pro-ANF 31-67. Immunoreactivityparalleled this radioimmunoassay curve as demonstrated with the 100, 200, and 400 Ad nornal human plasma and with 100 pd j plasma ofpatients with conges-5000 tive heart failure; this plasma diluted 1:10 (referred to as 10 p1-see text) and 1:5 (i.e., 20 Ad) as shown in this figure.
0.01% NaN3. To the redissolved sample, 100 Al (0.03 mg) rabbit IgG plus 100 Al of the respective antisera were added and incubated for 24 hours. Then, 100 ul 1251I-labeled peptides (10,000 cpm) were added, mixed, and incubated for 18 hours at 40 C. The precipitation of the antibody-bound tracer was accomplished by adding 100 Al goat anti-rabbit globulin after the above 18-hour period and incubating this mixture for 2 hours at room temperature. Each tube was then centrifuged at 3,000g for 20 minutes. The supernatant was aspirated and the pellet counted in a gamma counter. All determinations were performed in triplicate.
Analytic Separation of Pro-ANFs 1-30, 31-67, and 99-126 in Plasma by Reverse-Phase High-Pressure Liquid Chromatography Once the purity and retention times of these peptides had been determined by high-pressure liquid chromatography as described above, an ethanol-extracted sample of human pooled plasma from five control subjects was run over highpressure liquid chromatography with a Novapak C-18 (5 g) cartridge column. One-milliliter samples were collected each minute for 40 minutes. Separation was achieved with a linear gradient of 0-60% solvent B over 40 minutes at a flow rate of 1.0 ml/min. Solvent A was 0.1% trifluroacetic acid-H20, and solvent B was 0.1% trifluroacetic acidacetonitrile. The wavelength monitored was 210 nm. Each of the 40 samples (1 ml each) of plasma separated by high-pressure liquid chromatography were evaluated by radioimmunoassay to determine if pro-ANF 1-30, pro-ANF 31-67 and ANF were present in human plasma. The high-pressure liquid chromatography evaluation of plasma was repeated three times with similar results. There was less than 0. 5% crossreactivity with either ANF or pro-ANF 1-30.
Molecular Weight Determination of Immunoreactive Peptides Characterized by Gel Permeation Chromatography
To estimate the molecular weight of the immunoreactive peptides measured by the above radioimmunoassays, these peptides were characterized by gel permeation chromatography on a 2.5 x 80 cm column containing G-50 fine Sephadex (Pharmacia Fine Chemicals, Uppsala, Sweden), which separates peptides of 1,500-30,000 MW. Fivemilliliter samples of dried ethanol-extracted neat plasma reconstituted in 3 ml 10% acetic acid were loaded onto the gel column. This was eluted with 10% acetic acid at a rate of 3 ml/hr. To calibrate this column, 100 gl fresh dextran blue (2,000,000 MW), cytochrome C (12,384 MW), myoglobin II (6,210 MW), and "251-labeled ANF (3,081 MW) were included in each run as markers of void volumes (V0), molecular size, and total volume (V,). Each of the collected 1-ml fractionated samples was dried with controlled nitrogen flow and the resultant dried pellet reconstituted in 350 ,ul of the above radioimmunoassay buffer. One hundredmicroliter aliquots of each fraction were assayed for immunoreactivity with the pro-ANF 1-30, 31-67, and 99-126 radioimmunoassays and their elution position determined in reference to the molecular weight markers.12 The gel permeation chromatography was repeated three times for each of the radioimmunoassays.
Statistical Analysis
The data obtained by the above immunoreactive radioimmunoassays are illustrated as the mean±SEM. Statistical analyses of the data were by the Student's t test for unpaired values. To be considered statistically significant, we requiredp to be less than 0.05.
Results
Radioimmunoassay for Pro-ANF 1-30
A typical standard curve for the pro-ANF 1-30 radioimmunoassay is shown in Figure 1 . Evaluation of the sensitivity of this assay revealed that it had an IC50 of 180 fmol/tube and could detect as little as 40 fmol synthetic pro-ANF 1-30. Dilution curves of ANF, pro-ANF 31-67, normal human plasma, and plasma from patients with congestive heart failure are also shown. The pro-ANF 1-30 radioimmunoassay is specific with less than 0.5% cross-reactivity with either pro-ANF 31-67 or ANF as shown in Figure 1 . The antisera to pro-ANF 1-30 also had no detectable cross-reactivity with vasopressin, somatostatin, adrenocorticotropic hormone, insulin, or oxytocin. The intra-assay coefficient of variation for pro-ANF 1-30 radioimmunoassay was 4.8%, whereas its interassay variation was 8%. The parallelism of circulating immunoactive pro-ANF 1-30 with the standard curve was tested by the addition of 100, 200, and 400 gl normal human plasma and with 100-gul plasma from patients with congestive heart failure; this congestive heart failure plasma diluted 1: 10 and 1:5. A very good parallelism with serial dilution of plasma from both control subjects and patients with congestive heart failure was found (Figure 1 ). Recovery was examined by adding synthetic, unlabeled pro-ANF 1-30 at 100, 200, and 400 pg/ml with a recovery of 83.5+13.2% (SD) being found for pro-ANF 1-30.
Radioimmunoassay for Pro-ANF 31-67
A typical standard curve for pro-ANF 31-67 is shown in Figure 2 . This radioimmunoassay can detect as little as 35 fmol synthetic pro-ANF 31-67, and its IC50 of 120 fmol/tube reveals it to be a sensitive assay. It is also a specific assay as evi- Figure 2 where one observes that the cross-reactivity with these two peptides is less than 0.5%. The pro-ANF 31-67 antisera, likewise, has no detectable cross-reactivity with insulin, vasopressin, somatostatin, adrenocorticotropic hormone, or oxytocin. The intra-assay coefficient of variation of the pro-ANF 31-67 radioimmunoassay was 5.3% with an interassay coefficient of variation of 8%. The parallelism of circulating immunoactive pro-ANF 31-67 with the standard curve was examined by the addition of 100, 200, 300, 400, and 500 ,ul normal human plasma and with 100 gl plasma from patients with congestive heart failure; this plasma diluted 1: 10 and 1:5. Excellent parallelism with serial dilutions of plasma from both control subjects and patients with congestive heart failure was found (Figure 2) . Recovery for the pro-ANF 31-67 radioimmunoassay was examined by adding 100, 200, and 400 pg/ml synthetic, unlabeled pro-ANF 31-67 to normal pooled plasma. The recovery of pro-ANF 31-67 was 100.9+8.9%.
Radioimmunoassay ofAtrial Natriuretic Factor
In comparison to the above newly developed radioimmunoassays, our ANF radioimmunoassay has an intra-assay coefficient of variation of 5.7% and an interassay variation of 6.9%. It is, likewise, a specific assay with no detectable cross-reactivity with either pro-ANF 1-30 or pro-ANF 31-67 ( Figure 3 ). Likewise, it has less than 0.5% detectable cross-reactivity with vasopressin, insulin, adrenocorticotropichormone, oxytocin, or somatostatin. This ANF radioimmunoassay has excellent parallelism when examined with 100, 200, 400, and 800 gl human plasma from control subjects or with 100 ,ul plasma from patients with congestive heart failure and its 1:10 and 1:5 dilutions (Figure 3 ). It is a sensitive assay with an IC50 of 11 fmol and can detect as little as 1.4 fmol ANF. Recovery of unlabeled synthetic ANF (amino acids 99-126 of the prohormone) at 100, 200, and 400 pg/ml in this assay is 92+11% (+SD).
Comparison of Recovery of Pure Peptides With C-18 Columns Versus Ethanol Extraction
Recovery of the pure synthesized form of these three peptides as determined by high-pressure liquid chromatography was compared by adding the pure synthetic forms of pro-ANFs 1-30 and 31-67 and ANF to 1 ml human plasma on a Sep Pak C-18 column (Peninsula Labs, Belmont, California) with that of ethanol extraction described above. Before application to an activated 500-mg Sep-Pak column, the 1-ml plasma samples were acidified with 1 ml 0.1% trifluoroacetic acid and the resulting 2-ml plasma solutions were applied to the columns. The C-18 columns had been activated by adding first 60% CH3CN in 0.1% trifluoroacetic acid (4xl ml) and then 0.1% trifluoroacetic acid (4x5 ml). After the addition of plasma, the columns were rinsed with 0.1% trifluoroacetic acid (4x5 ml) and then eluted with 60% CH3CN in 0.1% trifluoroacetic acid (3 xl ml) into polypropylene tubes. The samples were then taken to dryness and assayed. Recovery of ANF with the C-18 columns was, on average, 75% compared with 92% for the ethanol extraction method. Recovery of pro-ANFs 1-30 and 31-67 with the C-18 columns averaged 56% (range, 43-75%) and 62% (range, 49-74%) versus 84% and 100%, respectively, for the ethanol extracted method. Because of the better recovery with the ethanol extracted method, all of the data described below are with this method.
High-Pressure Liquid Chromatography Evidence That Pro-ANFs 1-30 and 31-67 Exist in Human Plasma as Peptides Distinct From ANF Figure 4 depicts the analytic separation of pro-ANFs 1-30, 31-67, and 99-126 (ANF) by reversephase high-pressure liquid chromatography of a pooled sample of the pure synthetic forms of these peptides into three distinct peaks. By evaluating each of these peptides separately by high-pressure liquid chromatography, it was found that their respective retention times with respect to percent acetonitrile on a linear gradient were 32% for ANF, 39% for pro-ANF 31-67, and 48.5% for pro-ANF 1-30. Figure 4 also illustrates that in evaluation of ethanolextracted plasma from human control subjects, 99.5% of pro-ANF 1-30 when measured in 1-ml fractions resides in 1-ml fractions at 31, 32, and 33 minutes with fraction 32 having the predominant peak, which is where the single peak of the pure synthetic peptide 1-30 was found in a separate high-pressure liquid chromatography examination with respect to time. In Figure 5 , the results of assaying for pro-ANF 31-67 by radioimmunoassay of ethanol-extracted human plasma by highpressure liquid chromatography each of the 1-ml samples collected (1 ml/min) is illustrated. Essentially all (98%) of the pro-ANF 31-67 was found in samples at 26, 27, 28 , and 29 minutes with the predominant peak at 27 minutes, which is exactly where the pure synthetic peak of pro-ANF 31-67 is localized by high-pressure liquid chromatography. Approximately 2% of pro-ANF 31-67 by radioimmunoassay appeared in fractions 31-33. A similar study of ethanol-extracted human plasma over highpressure liquid chromatography with the 1-ml fractions evaluated with our ANF radioimmunoassay revealed that all of the ANF to be present in the high-pressure liquid chromatography fractions comigrating exactly with the pure synthetic high- pressure liquid chromatography peak for ANF (data not shown). The results of the investigations illustrated in Figures 4 and 5 suggest that pro-ANF 1-30 and 31-67 are present in human plasma as distinct peptides that have been cleaved from the prohormone at some time before our measuring them.
Characterization of Molecular Weights of the Endogenous Immunoreactive Peptides
Recognized by the Pro-ANF 1-30, Pro-ANF 31-67, and ANF Radioimmunoassays G-50 Sephadex gel permeation chromatography revealed that the pro-ANF 1-30 radioimmunoassay recognizes a peptide of approximately 10,000 MW, which is most consistent with it measuring the whole N-terminus of pro-ANF (i.e., amino acids 1-98) but without ANF (C-terminus of prohormone) attached to it as illustrated in Figure 6 . The pro-ANF 31-67 radioimmunoassay, on the other hand, recognizes mainly (more than 95%) a peptide of 3,900-4,000 MW, which corresponds closely with the known molecular weight of 3,878 for pro-ANF 31-67 ( Figure 6 ). The pro-ANF 31-67 radioimmunoassay also recognizes to a small extent (-5%) the 1-98 amino-acid N-terminus of pro-ANF ( Figure 6 ). Our ANF radioimmunoassay recognizes a peptide in human plasma of approximately 3,000 MW with the actual molecular weight of ANF being 3,081 ( Figure 6 ). This ANF radioimmunoassay does not recognize any part of Nterminus (i.e., amino acids 1-98) of pro-ANF ( Figure 6 ). None of these three radioimmunoassays recognized the whole pro-ANF (i.e., amino acids 1-126), which has a molecular weight of 13,000-13,500 and would have eluted between the V0 marked by the 2,000,000-MW dextran blue and cytochrome C (12,384 MW) shown in Figure 6 . Plasma Immunoreactive Pro-ANFs 1-98, 31-67, and 99-126 (ANF) Concentrations in Control Subjects The circulating concentrations of immunoreactive pro-ANF 1-98, immunoreactive pro-ANF 31-67, and immunoreactive ANF for each of 54 control subjects are shown in Table 1 . The circulating concentrations of these peptides were similar in both women and men. The mean concentration of immunoreactive pro-ANF 1-98 in 35 men was 533±33 fmol/ml; in 19 women, its concentration was 527±35 fmol/ml. The concentration of immunoreactive pro-ANF 31-67 in these 35 men was 376±24 fmol/ml, while its concentration in these 19 women was 361±27 fmol/ml. Seven of the women were on birth control pills (subjects 4, 27, 29, 33, 43, 51, and 53). The average values for immunoreactive pro-ANFs 1-98 and 31-67 in these seven women were 499±40 fmol/ml (±SEM) and 329±39 compared with 542±53 and 380±39 fmol/ml for the 12 women who were not on birth control pills. None of the 54 subjects were on any other medication. The average ANF concentration for women on birth control pills was 20±2 compared with 22±2 fmol/ml for those not on birth control pills. The difference in concentration of each of these circulating peptides for the women taking birth control pills compared with those women not taking birth control pills was not significant when analyzed with the Student's t test for unpaired values. FIGURE 6. Molecular weight characterization of the endogenous immunoreactive peptides recognized by the prohormone of atrial natriuretic factor (pro-ANF) 1-30 (o), pro-ANF 31-67 (A), and ANF (A) radioimmunoassays. G-50 sephadex gel permeation chromatography using dextran Vt blue (2, 000, 000 MW) to determine the void volume (V0) and cytochrome C (12,384 MJWV), myoglobin II (6,210 MW), and I25-ANF (3,081 MJWV) as molecular weight markers revealed that the pro-ANF 1-30 radioimmunoassay recognizes an immunoreactive peptide of approximately 10, 000 MW; the pro-ANF 31-67 radioimmunoassay a 4,000-MWpeptide and the ANF radioimmunoassay an immunoreactive peptide of 3, 000 MW. The total volume (VJ) collected was 84 ml (i. e., 1 ml/ fraction). To compare all three radioimmunoassays on the same figure, theirpercent binding was used on the ordinate rather than their immunoreactive concentrations (fmol/ml) as the immunoreactive concentrations are markedly higher (20fold) for the pro-ANF 1-30 and pro-ANF 31-67 radioimmunoassays versus that ofANF radioimmunoassay and, thus, all three radioimmunoassays would not fit on the same scale when shown as immunoreactive concentrations.
Plasma Immunoreactive Pro-ANFs 1-98, 31-67, and 99-126 in Patients With Congestive
Heart Failure
To determine if congestive heart failure has any effect on the circulating levels of these peptides, we studied 30 male patients with congestive heart failure. As seen in Table 2 , the circulating concentration of immunoreactive pro-ANFs 1-98, 31-67, and 99-126 (ANF) increased in patients with congestive heart failure. Each of the peptides increased proportionately to the severity of heart failure as determined by NYHA Classification. Thus, each of these peptides increased twofold for Class II, threefold to ninefold for Class III, and 10to 20-fold for Class IV patients with congestive heart failure. Pro-ANF 31-67 was found to increase proportionately more than ANF or pro-ANF 1-98 in the patients with more severe congestive heart failure (i.e., Class III and IV), and pro-ANF 31-67 was the only peptide whose circulating concentration was increased in Class I patients compared with control subjects.
Discussion
The use of highly sensitive and specific new radioimmunoassays in the present study demonstrates that a 10,000-MW peptide consistent with the whole N-terminus (amino acids 1-98) of the 126-amino-acid pro-ANF and a 4,000-MW peptide from the midportion of N-terminus consistent with amino acids 31-67 of the prohormone as well as ANF (i.e., amino acids 99-126) circulate normally in humans. The positive correlation of circulating concentration of the whole N-terminus of the prohormone with the circulating concentration of ANF in both normal persons and in persons with abnormalities of salt and water metabolism suggests that the N-terminus of the prohormone is cosecreted with ANF. Recently, in studies in rats'3,14 and humans,15 other investigators have also found that a 10,000-MW peptide consistent with the whole Nterminus (amino acids 1-98) circulates under normal conditions and is cosecreted with ANF (i.e., C-terminus consisting of amino acids 99-126 of the prohormone). The present study demonstrates for the first time that a 4,000-MW peptide cleaved from the midportion of the N-terminus of pro-ANF also circulates normally in humans. Gel permeation chromatography revealed that our pro-ANF 31-67 radioimmunoassay was recognizing mainly an immunoreactive peptide of 3,900-4,000 MW that is close to the actual molecular weight of 3,878 for pro-ANF 31-67. Because molecular weights determined by gel permeation chromatography are estimates, the molecular weight may actually be 3,878 (i.e., pro-ANF 31-67) or it may be even a little larger than 4,000 MW, suggesting a slightly longer amino acid sequence with amino acids added onto one or both ends of the pro-ANF 31-67 peptide. The exact amino acid sequence or number of amino acids of this approximately 4,000-MW peptide could not be determined from the present study. Analytic separation of the prohormone peptides in human plasma by high-pressure liquid chromatography followed by radioimmunoassay for pro-ANF 31-67 revealed, however, that this peptide in plasma coeluted exactly with pure synthetic amino acids 31-67 of the prohormone on high-pressure liquid chromatography, suggesting that the 4,000 -MW peptide recognized by the pro-ANF 31-67 radioimmunoassay is very similar to pro-ANF 31-67 itself.
The discovery of a 4,000-MW peptide from the midportion of the 10,000-MW N-terminus of pro-ANF circulating normally in human indicates that the 98-amino-acid N-terminus of the prohormone is cleaved by proteases either in the heart or in the circulation to form smaller peptides. Because the whole 1-98-amino-acid N-terminus of the ANF prohormone circulates in normal humans, one would suspect that this cleavage takes place in the circulation, but the simultaneous secretion from the heart of the whole N-terminus and of smaller peptides derived from the N-terminus cannot be ruled out from the present study. The C-terminus of the prohormone (i.e., ANF) is formed by proteolytic separation from the N-terminus.13 Both trypsin and thrombin can break the arginine-serine bond between amino acids 98 and 99 to form ANF. 13 Both trypsin and thrombin may also break a similar bond between amino acids 67 and 68 (arginine and aspartic acid) to form peptide fragment 1-67. In addition to trypsin and thrombin, there is a large family of aspartic proteases (E.C. 4.23) in the circulation whose preference for cleavage is between hydrophobic bonds such as those formed by arginine, lysine, phenylalanine, or leucine. [16] [17] [18] [19] [20] The aspartic proteases as well as trypsin and thrombin could cleave the Nterminus of pro-ANF via hydrolysis of the arginine linkage between amino acids 67 and 68 of the prohormone. When examining the amino acid sequence of the N-terminus of the prohormone, these aspartic proteases might also hydrolyze the lysine bond at amino acid 25 to form a peptide consisting of amino acids 25-67, which might be consistent with the approximately 4,000-MW peptide that circulates; these proteases might also hydrolyze the lysine bond at amino acid 16 to form peptides of 1-16 and 17-67. A peptide consisting of amino acids 17-67 of pro-ANF would have a molecular weight too large to correspond to the 4,000-MW peptide found to circulate in humans, and this would argue against this peptide being formed by proteolytic cleavage. These same aspartic proteases could theoretically also hydrolyze the leucine bond at amino acid 38, but this would result in peptide (i.e., 39-67) of approximately 3,000 MW, which would not correlate with the immunoreactivity found in the gel permeation studies. It is important to note that three peptides that could be formed by a protease attacking the acidic amino acid-aspartic acid bond would consist of amino acids 1-30, 31-67, and 79-98, a peptide that also has vasodilatory activity in vitro.5 Papin 3E, a proteolytic plant enzyme, does attack this aspartic acid bond avidly,21 but a similar proteolytic enzyme in human circulation has not been identified yet.
The above proteolytic processing of the Nterminus of pro-ANF to form the 4,000 -MW peptide in the midportion of the N-terminus also indicates that N-terminus is cleaved into at least three peptide segments (i.e., one peptide segment [amino acid 1-30] or a smaller peptide) cleaved from the N-terminus of this 4,000-MW peptide in midportion of pro-ANF and another peptide (68-98 or a smaller fragment of this peptide linkage) formed after cleavage of the bond between amino acids 67 and 68. Although the exact length of the peptide chains resulting after proteolytic processing of the prohormone is unknown, the high-pressure liquid chromatography examination of normal human plasma followed by pro-ANF 1-30 radioimmunoassay indicated that a peptide in plasma coeluted with more than 99% specificity with pure synthetic pro-ANF 1-30, suggesting pro-ANF 1-30 might be one of the peptides circulating after cleavage of the N-terminus of the prohormone as we have suggested previously. [22] [23] [24] The gel permeation studies of the present study, however, indicate that the pro-ANF 1-30 radioimmunoassay is immunologically recognizing a 10,000-MW peptide consistent with pro-ANF 1-98. Because the high-pressure liquid chromatography data demonstrated one major peak with our pro-ANF 1-30 radioimmunoassay, the pro-ANF 1-98 retention time on the highpressure liquid chromatography C-18 column must be very similar to that of pro-ANF 1-30. This pro-ANF 1-30 radioimmunoassay did detect two other small peptides in plasma run over highpressure liquid chromatography as observed in Figure 4 , which might be a further cleavage product(s) of pro-ANF 1-30. Although the exact consistency of the other peptides formed by the proteolytic processing of the N-terminus of the prohormone is unknown, it is important to note that both pro-ANF 1-30 and pro-ANF 79-98 of the N-terminus of the ANF prohormone as well as pro-ANF 31-67 have vasodilatory properties in vitro.5 These two peptides also have diuretic properties, although they are not as potent as pro-ANF 31-67 whose natriuretic and diuretic properties are nearly equal to ANF. 6 We have not as yet developed a radioimmunoassay to 79-98 because this peptide does not have a tyrosine in it to label with iodine, but its and pro-ANF 1-30's vasodilatory and diuretic effects5-7 suggest that they may be hormones if they circulate. Pro-ANF 31-67's ability to vasodilate aorta5 at concentrations at which it was found to circulate in human control subjects in the present study suggest that it as well as ANF is a hormone derived from the same ANF prohormone. Thus, two, and possibly four, hormones are contained in the 126-amino-acid pro-ANF, similar to the prohormone for proopiomelanocortin, which contains several hormones within its amino acid sequence.25 '26 Immunoreactive ANF levels have been demonstrated previously to be increased in patients with congestive heart failure.27,28 The present study demonstrates that in addition to the C-terminus, the 98amino-acid N-terminus and a 4,000-MW peptide consistent with pro-ANF 31-67 increase in response to increasing severity of the salt and water metabolism abnormality. The N-terminus of pro-ANF has also been reported to be increased when Class I and II patients were grouped together,15 but in the present study where groups with Classes I-IV congestive heart failure were separated into distinct groups, it was apparent that persons with Class I congestive heart failure do not have marked increases in the release of the 98-amino-acid Nterminus or the C-terminus of pro-ANF. The fact that the circulating concentration of pro-ANF 31-67, on the other hand, was markedly increased compared with that of the whole N-terminus in patients with Class I congestive heart failure suggests that in patients with even mild congestive heart failure, the 98-amino-acid N-terminus is being processed at a much more rapid rate compared with patients without congestive heart failure to obtain a peptide of approximately 4,000 MW. This interesting possibility (that the proteases are somehow recognizing that there is an abnormality of salt and water metabolism and respond to this abnormality by increasing proteolytic processing of the Nterminus of ANF prohormone to produce a 4,000-MW peptide with potent natriuretic and diuretic properties6) is a completely new concept in the physiologic regulation of salt and water metabolism, but it is one definite possibility suggested by the data of the present study. The other possibility is that pro-ANF 31-67, once cleaved from the N-terminus of the prohormone, is metabolized (i.e., degraded) at a much slower rate than the rest of the prohormone in patients with congestive heart failure-allowing its concentration to increase disproportionately to the rest of the prohormone. The present study of patients with congestive heart failure demonstrates that plasma levels of the Nterminus, C-terminus, and the peptide (pro-ANF 31-67) from the midportion of the N-terminus of pro-ANF are all sensitive and practical indicators of the severity of congestive heart failure. The determination of ANF, the whole N-terminus, or particularly pro-ANF 31-67's circulating concentration because it is the only assay that discriminates patients with Class I congestive heart failure from normal persons, may be useful to help accurately classify the severity of congestive heart failure.
